On April 3, 2014, Zeng, Qingping; Faris, Mary; Mollard, Alexis; Warner, Steven L.; Flynn, Gary A. published a patent.SDS of cas: 872046-08-7 The title of the patent was Preparation of heteroarylaminonaphthyridinone derivatives for use as multiple kinase pathway inhibitors. And the patent contained the following:
Title compounds I [R1 = (un)substituted azaheteroaryl; R2 = H, (un)substituted alkyl, cycloalkyl, heterocyclyl, etc.; R3 = H, alkyl, cycloalkyl, (un)substituted alkenyl, etc.], and their pharmaceutically acceptable salts, are prepared and disclosed as multiple kinase pathway inhibitors. Thus, e.g., II was prepared by a multistep procedure (preparation given). Select I were evaluated in DoHH2 cell cycle proliferation assays, e.g., II demonstrated an EC50 value of <1 μM. The experimental process involved the reaction of Methyl 2-(2,6-difluorophenyl)acetate(cas: 872046-08-7).SDS of cas: 872046-08-7
The Article related to naphthyridinone heteroarylamino preparation multiple kinase pathway inhibitor, Heterocyclic Compounds (One Hetero Atom): Other Areno- and Diarenopyridines (Acridines, Quinolizines, etc.) and other aspects.SDS of cas: 872046-08-7
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics